Full-Time

Senior Director

Posted on 9/23/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Biopharmaceutical company developing CNS therapies

Compensation Overview

$250k - $270k/yr

+ Annual bonus + Equity

New York, NY, USA

In Person

Category
Sales & Account Management (1)
Requirements
  • Bachelor’s degree is required
  • Fifteen plus years of related experience in the pharmaceutical, medical device, or biotech industry
  • At least three years of direct experience managing and developing teams
  • Ability to travel up to seventy percent
  • Demonstrated effective payer account (field) team leadership with comparable types of payers
  • Negotiation experience, preferably in competitive primary care therapeutic areas
  • Prior experience in longer-term execution (including complex multi-year contract and program management)
  • Experience managing projects and vendors
  • In-depth knowledge of the payer marketplace, payer practices, and legal and regulatory landscape pertinent to the industry
  • Demonstrated effective leadership in pre-launch, early, mid, and long range / full life cycle market access strategy formulation and execution
  • Strong understanding of the payer landscape and how payer decision making impacts providers and their patients
  • Ability to influence internal and external stakeholders
  • Excellent oral, written and presentation skills with ability to use numbers and data to tell a story, influence decision makers, and explain complex concepts clearly to a variety of audiences
  • Prior experience with budget development and control
  • Ability to translate the organization’s strategy into action by the team and build resilience into their team and so they are adaptive to changing and/or challenging market conditions
  • Previous product launch experience, preferably in the CNS space
  • Familiarity with current legal and regulatory landscape pertinent to the Payer market and industry
  • Strong communication and collaboration skills with the ability to effectively present ideas and influence others to achieve desired results and to drive consensus
  • Ability to thrive in a fast-paced environment with high expectations and accountability for the quality and timing of deliverables to meet company goals
Responsibilities
  • Lead a team of Account Directors responsible for developing and maintaining strong relationships at national and regional payer accounts within the Commercial, Medicare, Medicaid channels
  • Understanding and influencing multiple payer stakeholders
  • Developing and executing account specific strategies for national and regional payers
  • Communicating Axsome’s portfolio, corporate, and product(s) value proposition(s) that demonstrate the clinical and economic value of Axsome’s products with the Payer community
  • Educating Payers as they make formulary access decisions; this includes education on the value Axsome’s products provide payers and their patients, and our competitive position relative to alternatives
  • Negotiating and securing payer coverage for Axsome products that ensures a balance between affordable and easy access for patients while meeting the Net Sales goals of the company (i.e. contracting within approved financial metrics and in alignment with coverage strategy, as set by the Executive Leadership Team)
  • Recruit, develop, and assess Field talent
  • Engage internal parties to optimize idea generation and plan of action to implement strategic plans
  • Collaborate with other Market Access functions (e.g. Pricing & Contracting, Trade, Patient Services), Field Access Teams, Commercial, Medical, Legal, Regulatory, and Compliance partners to operationalize overall market access strategy
  • Function as a member of the Market Access Leadership Team and provide general management insights to optimize the overall long-term mission of the Market Access function
  • Collaborate closely with Pricing & Contracting to design, develop, and implement optimal contracting strategies and Payer coverage (as approved by the Executive Leadership Team), and ongoing assessment of the suitability of those strategies
  • Implementation of tools and tactics to support Market Access strategies for use with third party Payers
  • effective and collaborative working relationships with external business partners, including consultants, and data analytics vendors, as well as internal departments such as Marketing, Sales, Analytics, Training, Medical, Regulatory, Legal and Compliance
  • Collaborate with Sales Leadership to gather feedback and input on market dynamics, field needs and effectiveness of push and pull through tactics
  • Ensure the function operates in a fiscally sound manner in accordance with the objectives of Axsome
Desired Qualifications
  • MBA or MHA degree preferred
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders and focuses on research, development, and commercialization of medicines. Its lead product candidate, AXS-05, is an oral NMDA receptor antagonist being developed to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The company moves its pipeline through clinical trials and regulatory approvals to bring therapies to patients and earns revenue from drug sales, partnerships, and licensing. It differentiates itself by pursuing CNS-focused therapies with NMDA receptor targets and by pursuing designations like FDA Breakthrough Therapy to speed development, with a goal of improving patient outcomes and quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Auvelity Q1 2026 revenue hit $153.2M, up 59%, with $8B peak sales outlook post-Alzheimer's approval.
  • Total Q1 2026 revenue reached $191M, up 57%, beating estimates via sales force expansion.
  • Pipeline advances with AXS-12 NDA submission and AXS-20 addition for schizophrenia.

What critics are saying

  • Symbravo loses share to generic triptans and gepants due to high FDC pricing in 6-12 months.
  • AXS-12 NDA fails FDA approval from weak Phase III data, dropping stock 30-50% in 12-18 months.
  • Cash burns $305M reserves from sales force doubling before profitability in 18-24 months.

What makes Axsome Therapeutics Inc unique

  • Auvelity targets NMDA receptors for MDD and Alzheimer's agitation with FDA approvals.
  • Symbravo combines meloxicam-rizatriptan for acute migraine with long-term MOVEMENT trial benefits.
  • Sunosi treats narcolepsy daytime sleepiness with expanding Phase 3 indications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Yahoo Finance
Apr 8th, 2026
Axsome Therapeutics surges 33% annually since 2015 IPO, eyes $16B peak sales

Axsome Therapeutics, a midcap biotech, has delivered a compound annual growth rate of 33.32% since its 2015 IPO, potentially turning a $50,000 investment into nearly $1 million. However, replicating this performance over the next decade would require the company to reach a market capitalisation of approximately $157 billion. The company's 2025 revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity, a depression treatment. Auvelity may soon receive approval for treating agitation in Alzheimer's disease, expanding its addressable market to over five million US patients. Axsome Therapeutics' pipeline includes several phase 3 assets targeting over 150 million patients, with predicted peak sales exceeding $16 billion. Whilst the company shows promise for long-term growth through the 2040s, matching its historical performance remains unlikely.

Bitget
Mar 18th, 2026
Superstring Capital invests $6.84M in CNS pharma Axsome Therapeutics, stock up 27%

Superstring Capital Management invested $6.84 million in Axsome Therapeutics, purchasing 37,433 shares during Q4 2025, according to a SEC filing dated 17 February 2026. The investment represents nearly 4% of the fund's reported 13F assets. Axsome Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for central nervous system conditions including major depressive disorder, migraines and narcolepsy. The company has commercialised several treatments and recently launched a Phase 3 trial for solriamfetol in major depressive disorder with excessive daytime sleepiness. Axsome shares traded at $158.40 on Wednesday, up 27% over the past year, outpacing the S&P 500's 19% gain. The company reported $638.5 million in annual revenue, a 66% increase from 2024, with a market capitalisation of $8.1 billion.

Yahoo Finance
Mar 18th, 2026
Superstring Capital bets $6.8M on CNS drugmaker Axsome as Phase 3 trial begins and shares climb 27%

Superstring Capital Management has disclosed a new $6.84 million position in Axsome Therapeutics, acquiring 37,433 shares during the fourth quarter of 2025. The stake represents nearly 4% of the fund's assets under management. Axsome Therapeutics, a biopharmaceutical company specialising in central nervous system disorder treatments, has seen its shares rise 27% over the past year to $158.40. The company generated $638.5 million in revenue over the trailing twelve months, representing 66% growth from 2024. The company markets therapies for depression, migraine and sleep disorders whilst advancing a late-stage pipeline. Axsome recently initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, a segment with no approved treatments currently available.

Yahoo Finance
Mar 12th, 2026
Axsome's Auvelity surpasses $500M revenue, eyes approval for Alzheimer's agitation by April

Axsome Therapeutics reported Auvelity surpassed $500 million in revenue during its third year, with total company sales approaching $640 million in 2025. Auvelity posted approximately 68% year-over-year growth. The company's supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease agitation is under priority review, with a PDUFA date of 30 April 2026. This represents Axsome's key near-term regulatory catalyst, supported by three positive trials. Axsome is doubling its field force from 300 to 600 representatives by Q2, ahead of a potential launch. The company is advancing seven Phase III trials across multiple indications whilst maintaining approximately $323 million in cash to fund operations.

Yahoo Finance
Mar 6th, 2026
Axsome doubles salesforce to 600 reps as AUVELITY hits $155M quarter ahead of April Alzheimer's decision

Axsome Therapeutics reported $155 million in quarterly revenue for AUVELITY, annualising over $600 million just 13 quarters post-launch, though market penetration remains at approximately 0.2% of the antidepressant market. The company plans to double its salesforce from 300 to 600 representatives to drive uptake and support a potential Alzheimer's agitation launch. Over 50% of AUVELITY prescriptions are now monotherapy, with roughly 15% first-line and 35% first-switch therapy. Primary care clinicians account for about 30% of prescribers. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with an FDA decision expected on 30 April. Management reported revenue growth outpacing operating expenses by 3-to-1 in 2025, demonstrating strong operating leverage despite increased direct-to-consumer spending.

INACTIVE